{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hepatitis-c/management/active-hepatitis-c-infection/","result":{"pageContext":{"chapter":{"id":"70d87857-70c0-5a71-9e6b-8af6bcd3c53f","slug":"active-hepatitis-c-infection","fullItemName":"Scenario: Active hepatitis C infection","depth":2,"htmlHeader":"<!-- begin field a39a54d4-a205-4169-a0a4-a8d97ec4e1d9 --><h2>Scenario: Active hepatitis C infection</h2><!-- end field a39a54d4-a205-4169-a0a4-a8d97ec4e1d9 -->","summary":"Covers the primary care management of people with confirmed active hepatitis C infection.","htmlStringContent":"<!-- begin item dbdb7440-db54-4215-aba7-100e195186dd --><!-- begin field cfd6ebd0-7b85-4cbe-997f-acbc0157b9e7 --><p>From age 16 years onwards.</p><!-- end field cfd6ebd0-7b85-4cbe-997f-acbc0157b9e7 --><!-- end item dbdb7440-db54-4215-aba7-100e195186dd -->","topic":{"id":"a0ad57e4-0817-5b1a-9292-791ffa142703","topicId":"55070782-69db-4c7d-9e54-4da85ba4447b","topicName":"Hepatitis C","slug":"hepatitis-c","lastRevised":"Last revised in April 2020","chapters":[{"id":"e461354a-b186-5681-bc32-8cb96b08ae6b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8fa52488-05cf-5879-a691-c723a1430a1f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6d95b11c-1fc9-5914-9218-3de2e896a24f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"1d7e82a7-43ee-5524-b888-82cc0dff9059","slug":"changes","fullItemName":"Changes"},{"id":"64c4c883-1cd3-543b-8c3e-44ef84da58ac","slug":"update","fullItemName":"Update"}]},{"id":"939e5b5f-4d63-5220-a24d-332b6fc2cdde","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"27fa7468-2569-5880-ad98-f0c2a205677f","slug":"goals","fullItemName":"Goals"},{"id":"bb21c10e-b9bb-5e53-b00d-76f2175ac2a6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8743e312-a175-57be-ace4-aa2951fd7c6d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1d0624de-065c-5696-bc52-cd0a3fc96ff0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"652c4849-e314-5c2f-9aee-813e3412e330","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"95ff6fef-b360-5a40-ba6d-d511e9cbea9e","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"29bbbad3-26aa-5e9b-9381-9e82e2083ea1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ca0ed038-00d4-53b1-a0ec-0ee36dec9b4c","slug":"definition","fullItemName":"Definition"},{"id":"f4152d7e-511b-5b64-a7b0-fd3bbe90529e","slug":"transmission","fullItemName":"Transmission"},{"id":"56254cb4-0f61-544c-b3a3-46c8f0148e60","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fc3580a0-4415-5d71-b15e-b2d8b421e2c0","slug":"complications","fullItemName":"Complications"},{"id":"2eaad549-1687-5009-8092-731032ef4086","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"2ed6aea7-6c05-59b0-aa47-c293676c65b3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b827a0b9-4038-5046-bb7f-fd4b2965792d","slug":"who-to-screen-test","fullItemName":"Who to screen/test"},{"id":"415719a5-bfb8-5d93-9424-f5ce2b555354","slug":"how-to-test","fullItemName":"How to test"}]},{"id":"aa46d3c2-4a6e-544f-b6ad-e977b30cd44f","fullItemName":"Management","slug":"management","subChapters":[{"id":"70d87857-70c0-5a71-9e6b-8af6bcd3c53f","slug":"active-hepatitis-c-infection","fullItemName":"Scenario: Active hepatitis C infection"}]},{"id":"2a3a4ee7-054e-56d4-b866-d77b58228f83","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4097b54c-c716-53b0-8c01-d19a7b1efc90","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2e231f49-1646-5ad9-afbe-287aed9b553a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b0b10486-472e-53a7-8975-8005079c99ae","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"54258242-86fa-5282-aedd-bdcd1f636a6f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"02b519b7-6884-5329-b15d-752976d77af7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ccf574ec-19fa-5d3c-90f6-3a1468826262","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6765ac6b-398f-56e9-b9cc-2df0a4010bbd","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"aa46d3c2-4a6e-544f-b6ad-e977b30cd44f","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"a30cc536-61d6-5110-ba74-a12ce04d0157","slug":"initial-management-of-active-hepatitis-c","fullItemName":"Initial management of active hepatitis C","depth":3,"htmlHeader":"<!-- begin field 4c0fc366-a985-47a7-94aa-b8803a3c589f --><h3>How should I manage a person with hepatitis C in primary care?</h3><!-- end field 4c0fc366-a985-47a7-94aa-b8803a3c589f -->","summary":null,"htmlStringContent":"<!-- begin item 0a1ab92c-e6f8-4a43-94e5-460a086fd606 --><!-- begin field ee99a82d-c132-45d9-94b9-9bcbcfdbe2e6 --><ul><li><strong>People with hepatitis C virus (HCV) infection should be under the care of a </strong><strong>hepatologist or specialist gastroenterologist.</strong><ul><li><strong>If acute hepatitis C virus (HCV) infection is suspected</strong> (hepatitis C antibody positive with <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-c/diagnosis/who-to-screen-test/\">clinical features</a> of acute hepatitis and/or a likely recent <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-c/background-information/transmission/\">source of transmission</a> is identified):<ul><li>Arrange a same-day assessment or seek immediate specialist advice.</li></ul></li><li><strong>If chronic HCV infection is suspected</strong> (hepatitis C antibody positive and ribonucleic acid positive with no clinical features of acute hepatitis):<ul><li>Arrange an urgent referral. Confirm the person's address and telephone number at the time of referral, and use the practice's address for correspondence if necessary, for example if the person frequently changes address, has an insecure address, or is homeless.</li></ul></li></ul></li><li><strong>Notify the local Health Protection Team</strong> of suspected cases of acute viral hepatitis by completing a <a data-hyperlink-id=\"dcc260c2-5dd2-4b98-8148-ab9301267bdd\" href=\"https://www.gov.uk/government/publications/notifiable-diseases-form-for-registered-medical-practitioners\" rel=\"noopener\" target=\"_blank\">notification form</a> immediately.<ul><li>Inform the person that this is being done.</li></ul></li><li><strong>Whilst awaiting <strong><a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-c/management/active-hepatitis-c-infection/#specialist-management\">specialist management</a></strong>:</strong><ul><li><strong>Arrange the following baseline investigations:</strong><ul><li>Full blood count — to check for anaemia, neutropenia, and thrombocytopenia.</li><li>Urea and electrolytes, creatinine, and estimated glomerular filtration rate (eGFR) — chronic kidney disease is a possible <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-c/background-information/complications/\">extrahepatic manifestation</a> of HCV infection.</li><li>Liver function tests, especially alanine aminotransferase (ALT) and gamma glutamyl transferase (GGT). Note that these do not accurately indicate the extent of liver damage or severity of hepatitis C infection.</li><li>Clotting screen.</li><li>HbA1c — diabetes mellitus is a possible <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-c/background-information/complications/\">extrahepatic manifestation</a> of HCV infection.</li><li>Thyroid function tests (TFTs) — antiviral therapy can cause thyroid dysfunction.</li><li>Ferritin level — to assess iron stores (can be elevated in chronic hepatitis C).</li><li>Hepatitis B surface antigen (HBsAg) or antibody to hepatitis B core antigen (anti-HBc) — to check hepatitis B status. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hepatitis-b/\">Hepatitis B</a> for more information.</li><li>Hepatitis A immunoglobulin M (HAV-IgM) — to check hepatitis A status. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hepatitis-a/\">Hepatitis A</a> for more information.</li><li>HIV test, even if the person has recently been tested. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hiv-infection-aids/\">HIV infection and AIDS</a> for more information.</li></ul></li><li><strong>Consider screening for other sexually transmitted infections (STIs) </strong>if hepatitis C infection is thought to have been sexually acquired. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/chlamydia-uncomplicated-genital/\">Chlamydia - uncomplicated genital</a>, <a class=\"topic-reference external-reference\" href=\"/topics/gonorrhoea/\">Gonorrhoea</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/syphilis/\">Syphilis</a> for more information.</li><li><strong>Give <strong><a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-c/management/active-hepatitis-c-infection/#information-advice\">advice</a></strong> on:</strong><ul><li>Measures to reduce the risk of disease progression, such as stopping smoking.</li><li>Measures to prevent the spread of the infection, such as not sharing razors, toothbrushes, toiletries, or other items that may be contaminated with blood.</li><li>The risk of sexual transmission, which is greater in people co-infected with HIV and with risky sexual practices (for example anal sex).</li><li>Partner notification and contact tracing.</li><li>Sources of additional information and support.</li></ul></li></ul></li></ul><!-- end field ee99a82d-c132-45d9-94b9-9bcbcfdbe2e6 --><!-- end item 0a1ab92c-e6f8-4a43-94e5-460a086fd606 -->","subChapters":[{"id":"52bfddde-5329-5582-afcb-577ef100b421","slug":"specialist-management","fullItemName":"Specialist management","depth":4,"htmlHeader":"<!-- begin field 86586567-c8cc-487e-a0f6-0350c8cb9859 --><h4>Specialist management</h4><!-- end field 86586567-c8cc-487e-a0f6-0350c8cb9859 -->","summary":null,"htmlStringContent":"<!-- begin item f7f17b56-0a6b-4d6b-84ee-80b8187a8901 --><!-- begin field 24540247-e98f-4656-a88a-6047bba1fd1b --><p><strong>All people under specialist services for hepatitis C management should be offered integrated multidisciplinary care (including specialist nurse input) to maximise their uptake of, and retention in, services and to provide ongoing monitoring and support. </strong></p><ul><li><strong>Around 15–45% of people with acute hepatitis C virus (HCV) infection spontaneously clear the virus within 6 months of infection without any treatment </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">Ahmad, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">WHO, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">WHO, 2019</a>]<strong>.</strong><ul><li>If spontaneous resolution (defined as loss of HCV ribonucleic acid [RNA] within the first 6 months) occurs, no antiviral treatment is necessary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">BASHH, 2017a</a>]. </li><li>If needed, treatment should be started promptly. There is clear evidence that treatment given during the acute phase is more likely to clear infection and reduces the risk of chronic HCV infection and progression of liver disease than treatment in the chronic phase [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">BASHH, 2017a</a>]. Treatment should be the same as for chronic infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">BMJ, 2019</a>].</li></ul></li><li><strong>All people with chronic HCV infection should be considered for antiviral therapy, which is always initiated by a specialist.</strong><ul><li>The goal of treatment is to eradicate the virus, achieve a sustained virological response (SVR), and prevent disease progression [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">Ahmad, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">BMJ, 2019</a>]. SVR (undetectable HCV RNA in the blood 12 weeks after treatment completion) is considered equivalent to a cure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">PHE, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">WHO, 2018</a>].</li><li>The treatment regimen and duration will depend on the HCV genotype, viral load, severity of liver disease, prior HCV treatment history, the presence of comorbidities, and the person's ability to tolerate treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">BASHH, 2017a</a>]. </li><li>Interferon-based treatment regimens are no longer recommended for HCV infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">Ahmad, 2017</a>], as direct-acting antivirals (DAAs) are now considered first-line treatment. DAAs target different stages in the HCV lifecycle and are successful for over 90% of people with HCV infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">PHE, 2018a</a>]. <ul><li>The treatment is usually a once daily, oral tablet regimen for either 8 or 12 weeks and is most effective when given before the onset of cirrhosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">PHE, 2018a</a>].</li><li>DAAs are well tolerated with minimal adverse effects and result in high rates of SVR [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">PHE, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">WHO, 2018</a>].</li></ul></li><li>The National Institute for Health and Care Excellence (NICE) has approved the use of the DAAs alone or in certain combinations for the treatment of different genotypes of chronic HCV infection. For more information, see the following NICE guidelines:<ul><li><a data-hyperlink-id=\"70151744-2462-47e6-b733-aba100a91009\" href=\"http://www.nice.org.uk/guidance/ta330/\" title=\"External website\">Sofosbuvir for treating chronic hepatitis C</a></li><li><a data-hyperlink-id=\"f9924b56-a535-4ad9-9643-aba100a9106b\" href=\"http://www.nice.org.uk/guidance/ta363\" title=\"External website\">Ledipasvir-sofosbuvir for treating chronic hepatitis C</a></li><li><a data-hyperlink-id=\"398df98b-3dd2-4c92-b64b-aba100a910a4\" href=\"https://www.nice.org.uk/guidance/TA365\" title=\"External website\">Ombitasvir-paritaprevir-ritonavir with or without dasabuvir for treating chronic hepatitis C</a></li><li><a data-hyperlink-id=\"af7c0c44-2fe3-43fc-a211-aba100e58e7b\" href=\"https://www.nice.org.uk/guidance/ta413\">Elbasvir–grazoprevir for treating chronic hepatitis C</a></li><li><a data-hyperlink-id=\"e4dcb2db-e99f-4c0f-ad38-aba100a910ce\" href=\"https://www.nice.org.uk/guidance/ta430\" title=\"External website\">Sofosbuvir-velpatasvir for treating chronic hepatitis C</a> </li><li><a data-hyperlink-id=\"d3054494-99d3-40a4-8b32-aba100a91127\" href=\"https://www.nice.org.uk/guidance/ta499\" title=\"External website\">Glecaprevir–pibrentasvir for treating chronic hepatitis C</a></li><li><a data-hyperlink-id=\"62adda0d-d3f3-43af-8cbd-aba100a910fb\" href=\"https://www.nice.org.uk/guidance/ta507\" title=\"External website\">Sofosbuvir-velpatasvir-voxilaprevir for treating chronic hepatitis C</a></li></ul></li></ul></li><li><strong>Specialist investigations are carried out to assess the state of infection and the progression of liver disease. </strong><ul><li>Blood tests may include:<ul><li>Viral load — to assess response to treatment.</li><li>Clotting studies — clotting may be affected if there is significant liver damage.</li><li>Autoantibodies — which are non-specific markers for autoimmune disease.</li></ul></li><li>Transient elastography can be offered to diagnose cirrhosis. If unsuitable, liver biopsy can be offered.</li><li>Liver ultrasound is carried out in people with advanced fibrosis or cirrhosis to screen for hepatocellular cancer. Ultrasound cannot accurately assess the degree of inflammation or liver fibrosis, or predict the prognosis.</li><li>Liver biopsy<strong> </strong>may be considered in individual cases, for example to assess the extent of liver damage caused by inflammation, fibrosis, or cirrhosis; to identify iron overload; and to exclude other causes of liver damage.</li></ul></li></ul><!-- end field 24540247-e98f-4656-a88a-6047bba1fd1b --><!-- end item f7f17b56-0a6b-4d6b-84ee-80b8187a8901 -->","subChapters":[]},{"id":"63f76b85-98cf-5d04-9cee-f995c8cd1aa5","slug":"basis-for-recommendation-86f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f02bdb48-1c45-4192-902a-e51f75c28258 --><h4>Basis for recommendation</h4><!-- end field f02bdb48-1c45-4192-902a-e51f75c28258 -->","summary":null,"htmlStringContent":"<!-- begin item 86ff9307-20bd-4b1d-93a1-78a3cdc8486b --><!-- begin field 1a247d69-1b58-4c5e-9f46-0247cd8f05ba --><p>These recommendations are largely based on the Public Health England (PHE) guideline <em>Hepatitis C: migrant health guide </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">PHE, 2017c</a>], the World Health Organization (WHO) <em>Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">WHO, 2018</a>], WHO Factsheet on <em>Hepatitis C</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">WHO, 2019</a>], the British Association for Sexual Health and HIV (BASHH) guideline <em>2017 interim update of the 2015 BASHH national guidelines for the management of viral hepatitides</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">BASHH, 2017a</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline <em>Management of hepatitis C</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">SIGN, 2013</a>], the National Institute for Health and Care Excellence (NICE) guideline <em>Hepatitis B and C testing: people at risk of infection </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">NICE, 2013</a>], and on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">Ahmad, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">BMJ, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">Spearman, 2019</a>].</p><h5>Specialist care</h5><ul><li>People identified as positive for hepatitis C virus (HCV) infection should be referred for specialist assessment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">PHE, 2017c</a>].</li><li>Referral to specialist care should be considered for all people with active HCV infection and not be restricted to potential candidates for antiviral treatment. Specialist clinics are often a source of information for people with HCV infection and their family/carers, including health promotion and methods of avoiding secondary transmission of the virus [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">SIGN, 2013</a>].</li><li>People with acute HCV infection require clinical and laboratory monitoring (looking for spontaneous viral clearance) for the initial 3 months following diagnosis, as they will often have a self-limiting illness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">SIGN, 2013</a>].</li><li>All people with chronic HCV infection should be considered for antiviral treatment, which is always initiated by a specialist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">SIGN, 2013</a>].<ul><li>Specialist assessment and monitoring is needed to determine if further management is required, including screening for hepatocellular cancer (HCC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">SIGN, 2013</a>].</li><li>Early treatment to eradicate HCV infection is associated with increased and sustained viral response rates and can reduce the risk of complications, such as end-stage liver disease and HCC [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">NICE, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">Ahmad, 2017</a>].</li></ul></li></ul><h5>Notifying the local Health Protection Team</h5><ul><li>The recommendation on notification of suspected acute viral hepatitis is based on the BASHH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">BASHH, 2017a</a>].</li></ul><h5>Additional investigations</h5><ul><li>The recommendations on additional baseline investigations are based on expert opinion in the SIGN guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">SIGN, 2013</a>] and the BASHH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">BASHH, 2017a</a>].</li><li>The recommendation to screen for other sexually transmitted infections (STIs) is based on the BASHH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">BASHH, 2017a</a>].</li></ul><!-- end field 1a247d69-1b58-4c5e-9f46-0247cd8f05ba --><!-- end item 86ff9307-20bd-4b1d-93a1-78a3cdc8486b -->","subChapters":[]}]},{"id":"2dbeaf01-179d-5a18-9143-b4df9829e59c","slug":"follow-up-in-primary-care","fullItemName":"Follow up in primary care","depth":3,"htmlHeader":"<!-- begin field 175606dd-7b9a-480f-b69c-9a0429ca06f0 --><h3>How should I follow up a person with hepatitis C in primary care?</h3><!-- end field 175606dd-7b9a-480f-b69c-9a0429ca06f0 -->","summary":null,"htmlStringContent":"<!-- begin item b0d1d117-1592-4392-81e2-7fa3d649b8cd --><!-- begin field a0fae051-d49e-4e8c-abe0-dc6778403149 --><p><strong>People with chronic hepatitis C infection undergoing <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-c/management/active-hepatitis-c-infection/#specialist-management\">specialist treatment</a> should be under the care of a hepatologist or specialist gastroenterologist, for ongoing monitoring and management.</strong></p><ul><li>Ensure the person is attending specialist appointments, and provide appropriate support if needed to help the person attend.</li><li>Provide the person with sources of <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-c/management/active-hepatitis-c-infection/#information-advice\">information and support</a> on hepatitis C and its treatment.</li><li>Monitor the person for adverse effects of specialist treatment, and manage appropriately.<ul><li>Hypoglycaemia — monitor glucose levels closely in people with diabetes during treatment with <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-c/management/active-hepatitis-c-infection/#specialist-management\">direct-acting antivirals</a> (DAAs), particularly within the first 3 months of treatment, and modify diabetes treatment when necessary. Concurrent treatment with antidiabetic drugs may result in symptomatic hypoglycaemia.</li><li>Fluctuations of international normalised ratio (INR) — monitor INR closely in people on anticoagulant treatment and, if necessary, adjust the dose of the anticoagulant. Changes in liver function due to treatment with DAAs may result in fluctuations of INR values.</li></ul></li><li>Give the person ongoing <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-c/management/active-hepatitis-c-infection/#information-advice\">lifestyle advice</a> to reduce the risk of disease progression, such as stopping smoking.</li><li>Offer all people at continued risk of a blood-borne infection immunization against hepatitis A and B (available free on the NHS for this indication). For more information, see the sections on <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-travel/background-information/diseases-commonly-requiring-vaccination/#hepatitis-a\">Hepatitis A</a> and <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-travel/background-information/other-diseases-requiring-vaccination/#hepatitis-b\">Hepatitis B</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-travel/\">Immunizations - travel</a>.</li><li>Advise the person that they may be eligible for ex gratia financial compensation if they:<ul><li>Were alive on the 29 August 2003, <em>and</em></li><li>Have chronic hepatitis C that is attributable to NHS treatment with blood or blood products received before September 1991.<ul><li>For more information, see the <a href=\"http://www.skiptonfund.org/\" data-hyperlink-id=\"30b76015-b0af-471d-895b-a993004958b1\">Skipton Fund website</a>, which has been established by the Department of Health to administer the scheme and make payments to relevant claimants.</li></ul></li></ul></li></ul><!-- end field a0fae051-d49e-4e8c-abe0-dc6778403149 --><!-- end item b0d1d117-1592-4392-81e2-7fa3d649b8cd -->","subChapters":[{"id":"eef8f0e8-1001-54a5-aed4-115bbd476c58","slug":"basis-for-recommendation-56f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 88a9810a-a7bc-4945-a35e-c6ec54c01be7 --><h4>Basis for recommendation</h4><!-- end field 88a9810a-a7bc-4945-a35e-c6ec54c01be7 -->","summary":null,"htmlStringContent":"<!-- begin item 56ff4b0e-57f4-4c1c-90cb-199c7433a3c4 --><!-- begin field bc9a9c36-ad09-4f3c-ad23-a2f9809dac44 --><p>These recommendations are largely based on the British Association for Sexual Health and HIV guideline (BASHH) <em>2017 interim update of the 2015 BASHH national guidelines for the management of viral hepatitides</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">BASHH, 2017a</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline <em>Management of hepatitis C</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">SIGN, 2013</a>], and the Medicines and Healthcare products Regulatory Agency (MHRA) guidelines <em>Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">MHRA, 2017</a>] and <em>Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">MHRA, 2018</a>].</p><h5>Adverse effects of specialist treatment</h5><ul><li>The information on hypoglycaemia and fluctuations of international normalised ratio (INR) are based on the MHRA guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">MHRA, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">MHRA, 2018</a>].</li></ul><h5>Offering hepatitis A and B immunizations</h5><ul><li>People with hepatitis C infection should be offered immunization against hepatitis A and B because co-infection with hepatitis A can increase the risk of acute fulminant hepatitis, and co-infection with hepatitis B can lead to hepatic decompensation and a worse prognosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">SIGN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">BASHH, 2017a</a>].</li></ul><!-- end field bc9a9c36-ad09-4f3c-ad23-a2f9809dac44 --><!-- end item 56ff4b0e-57f4-4c1c-90cb-199c7433a3c4 -->","subChapters":[]}]},{"id":"6b7d62fa-678a-5f05-acd8-00a392e502b1","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field 1c3ab103-2c79-401b-aa00-ab990168e7cd --><h3>What information and advice should I give people with hepatitis C?</h3><!-- end field 1c3ab103-2c79-401b-aa00-ab990168e7cd -->","summary":null,"htmlStringContent":"<!-- begin item a526d690-b6c8-4cf2-8969-ab990168e78b --><!-- begin field 2be4eee1-3ef3-4a58-b6a0-ab990168e7cd --><ul><li><strong>Give a detailed explanation of the condition</strong> with particular emphasis on the long-term implications for the health of the person and their partner(s). Reinforce this by providing sources of additional information and support, such as:<ul><li>The NHS website (<a href=\"http://www.nhs.uk/conditions/hepatitis-c/\" data-hyperlink-id=\"77f76bd0-3952-486b-8b6b-ab99016f3f17\">www.nhs.uk</a>).</li><li>The Hepatitis C Trust (<a href=\"http://www.hepctrust.org.uk/information\" data-hyperlink-id=\"d544ca06-8d84-447e-8541-ab99016f3f34\">www.hepctrust.org.uk</a>).</li><li>The British Liver Trust (<a href=\"https://britishlivertrust.org.uk/information-and-support/living-with-a-liver-condition/liver-conditions/hepatitis-c/\" data-hyperlink-id=\"c055614b-7800-41af-85ed-ab99016f3f63\">www.britishlivertrust.org.uk</a>). </li><li>Liver4Life (<a href=\"https://7e6f3ed4-7ba8-4437-a806-932f94e07fd1.filesusr.com/ugd/a2ce3b_df628db350b84826956a25fe546ff805.pdf\" data-hyperlink-id=\"3ee5d755-991d-4706-8c20-aba100baa19a\">www.liver4life.org.uk</a>).</li><li>HIV-i-Base (<a href=\"http://i-base.info/guides/hepc/hepatitis-c-transmission\" data-hyperlink-id=\"f24939b6-b8ff-4604-95af-aba100baa1af\">i-base.info</a>). </li><li>Terrence Higgins Trust (<a href=\"https://www.tht.org.uk/hiv-and-sexual-health/sexual-health/stis/hepatitis/hepatitis-c\" data-hyperlink-id=\"f5110a5e-fe0e-411b-ad36-aba100baa212\">www.tht.org.uk</a>). </li></ul></li><li><strong>Advise on measures to reduce the risk of disease progression, including that they should:</strong><ul><li>Maintain a healthy body weight and diet, as obesity increases the risk of fatty liver disease and progression to cirrhosis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>.</li><li><div>Stop smoking, if appropriate. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.</div></li><li>Stop or reduce alcohol consumption, as alcohol is an important predictor of disease progression. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a>.</li></ul></li><li><strong>Advise on measures to prevent the spread of the infection of hepatitis C.</strong><ul><li>Advise the person that there is currently no available vaccine or immunoglobulin preparation that will prevent transmission. Spontaneous resolution of infection and previous successful treatment <em>do not</em> provide protection if further hepatitis C virus (HCV) exposure occurs. </li><li>Advise that they should not:<ul><li>Donate blood or carry an organ donor card.</li><li>Share razors, toothbrushes, toiletries, or other items that may be contaminated with blood.</li><li>Share any drug paraphernalia related to injecting, snorting, or smoking illicit drugs — offer referral to specialist drug services, such as needle exchange schemes, to consider opioid substitution therapy for people who currently inject drugs, and advice on safe snorting techniques. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/opioid-dependence/\">Opioid dependence</a>.</li></ul></li><li>Encourage the person to discuss their infection with their household and anyone they share injecting drug equipment with so they can be tested for hepatitis C.</li></ul></li><li><strong>Advise on the risk of sexual transmission.</strong><ul><li>Explain that sexual transmission of HCV occurs infrequently in monogamous, heterosexual relationships. The risk is increased:<ul><li>In people with multiple partners or those at risk for sexually transmitted infections (STIs). </li><li>In HIV-positive people, particularly in men who have sex with men. </li><li>With risky sexual practices (for example anal sex).</li></ul></li><li>The person has a duty of responsibility to practice safe sex if they have multiple sexual partners. In addition, this will protect against other STIs (for example hepatitis B and HIV).</li><li>In people with chronic HCV infection, it seems likely that if condoms are used consistently then sexual transmission will be avoided, but given the very low rates of transmission outside of HIV co-infection, monogamous partners may choose not to use them. </li><li>Advise people at higher risk of sexual transmission to always practice safe sex and use condoms.</li><li>Encourage the person to discuss their infection with their sexual contact(s) so they can be tested for hepatitis C.</li></ul></li></ul><!-- end field 2be4eee1-3ef3-4a58-b6a0-ab990168e7cd --><!-- end item a526d690-b6c8-4cf2-8969-ab990168e78b -->","subChapters":[{"id":"0d2d73e6-b898-5614-b388-c53f699ec937","slug":"basis-for-recommendation-d33","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fc9cd687-977e-4f08-88ad-aba6011ccfa5 --><h4>Basis for recommendation</h4><!-- end field fc9cd687-977e-4f08-88ad-aba6011ccfa5 -->","summary":null,"htmlStringContent":"<!-- begin item d336bb42-89d9-4e65-8b6b-aba6011ccf5d --><!-- begin field 194fc639-f1e0-4e3e-85b1-aba6011ccfa5 --><p>These recommendations are largely based on the World Health Organization (WHO) <em>Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">WHO, 2018</a>], WHO Factsheet on <em>Hepatitis C</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">WHO, 2019</a>], the British Association for Sexual Health and HIV (BASHH) guideline <em>2017 interim update of the 2015 BASHH national guidelines for the management of viral hepatitides</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">BASHH, 2017a</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline <em>Management of hepatitis C</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">SIGN, 2013</a>], and on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">Ahmad, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">BMJ, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">Spearman, 2019</a>].</p><!-- end field 194fc639-f1e0-4e3e-85b1-aba6011ccfa5 --><!-- end item d336bb42-89d9-4e65-8b6b-aba6011ccf5d -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}